Condition: Alopecia Areata (AA) · Sponsor: Aldena Therapeutics
The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug) or an untreated area. Study participants will have treatment areas selected on the scalp to receive ALD-102 Solution (drug), placebo (saline solution) or to remain untreated. Injections will occur once every 4 weeks for a treatment period of 8 weeks.
This description comes directly from the study's public registry record.
Chief Scientific Officer · +44 2045915017 · info@aldenatherapeutics.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Research Institute | Thousand Oaks, California, United States | Recruiting |
| Options Research Group | West Lafayette, Indiana, United States | Recruiting |
| The Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Dermatology Specialists of Spokane | Spokane, Washington, United States | Recruiting |
| The Centre for Clinical Trials | Oakville, Ontario, Canada | Recruiting |
| Innovaderm | Montreal, Quebec, Canada | Recruiting |
| Centre de Recherche Saint-Louis | Québec, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06826196